Which, if enacted, would likely have an impact on… the labor market ... A caller mentioned disappointing news regarding Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) drug suzetrigine ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown its team year-over-year. At a time when many life sciences companies are ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business.

Vertex reports Q4 earnings Monday, with Wall Street expecting $4.03 EPS and $2.78 billion revenue. Strong technicals support VRTX stock, but selling pressure and pipeline execution remain key ...

KING OF PRUSSIA, Pa. (AP) — KING OF PRUSSIA, Pa. (AP) — Vertex, Inc. (VERX) on Thursday reported a loss of $67.8 million in its fourth quarter. On a per-share basis, the King Of Prussia, ...

Vertex Pharmaceuticals recently obtained approval for its non-opioid pain medication. The drug could become a blockbuster and a key part of Vertex's portfolio. The stock has been rising in value ...